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Summary.-Blood lymphocytes from 47 patients with lung carcinoma have been
tested for cytotoxicity against cells isolated from the autologous tumour. Significant
cytotoxic potential was found in 15 cases. The effectors were also tested against
allogeneic tumour targets from lung and other sites. Reactions were only rarely
detected (2/32 positive against lung and 1/13 positive against non-lung cells). The
restriction of cytotoxicity to the autologous combination was also apparent in in
vitro-generated effectors. Blood lymphocytes were co-cultivated with autologous
tumour and subsequently tested against autologous or allogeneic targets. Cytotoxicity
was found in 13/17 lung tumours against autologous tumour, with no reactions
recorded against allogeneic tumour targets, but onecasepositive againstthe K562 cell
line. These data suggest either the expression of individually distinct antigens on
human pulmonary neoplasms, or the requirement for histocompatibility between
target and effector in cytotoxicity reactions in man, and therefore differ from pre-
viously described patterns of lymphocytotoxicity against human tumours.
THE definition of antigenic specificities
on cells cuiltured from human malignancies
by lymphocytotoxicity testing has been
controversial since the description of
natural killeractivity (NK)inhumanblood
leukocytes (Takasugi et al., 1973). Thus al-
though differences in cytotoxic potential
may be apparent between leukocytes from
lung cancer patients and healthy donors
against lung-tumour-derived targets, cells
cultured from different types of tumour,
normal and foetal lung may also show
susceptibility to lysis (Vose et al., 1975) and
patterns ofreactivity are difficult to inter-
pret on the basis of disease specificity, as
earlier reports suggested (Hellstr6m et al.,
1971; Baldwin et al., 1973). In a recent
publication the detection of T-cell-medi-
ated lymphocytotoxic responses against
freshly isolated human tumour cells was
described (Vose et al., 1977). The advant-
age of this methodology is that prolonged
culture of the target cells which may in-
crease susceptibility to NK effectors (De
Vries et al., 1974) is not attempted and
selection of cells adapted to survival in
vitro and gain or loss of cell surface anti-
gens does not arise after initial separation.
Additionally, assays are performed in
autologous combination. This latter factor
may be ofcritical importance in the defini-
tion of tumour antigenicity, since in ani-
mal models (Zinkernagel and Doherty,
1974; Shearereta,l., 1975)andmorerecently
in humans (Coulmy et al., 1977; Dickmeiss
et al., 1977), the necessity of histocom-
patibility between effector and target cells
for the detection ofT-cell cytotoxicity has
been stressed. It has also been reported
that, with freshly isolated melanoma cells
as targets in microcytotoxicity, assays
reactions, although infrequent, were con-
fined to the autologous tumour (Currie et
al., 1971).
In the present study, blood lymphocytes
from lung cancer patients enriched for T-B. M. VOSE, F. VANKY, M. FOPP AND E. KLEIN
cells by passage through nylon wool
columns have been tested for cytotoxicity
against autologous and allogeneic tumour
targets to investigate the patterns of re-
activity in this most prevalent of human
malignancies. The generation of effectors,
in vitro, by co-cultivation of lymphocytes
with autologous tumour cells has also been
attempted.
MATERIALS AND METHODS
Lymphocytes.-Heparinized blood samples
(30-50 ml) were taken preoperatively before
medication. The blood was allowed to stand
for 1 h at room temperature and the leuco-
cyte-rich plasmaseparatedonFicoll-Isopaque
gradients by centrifugation (800 g for 10 min)
as described previously (Vose et al., 1977).
Adherent cells were removed by incubation
in 75 cm2 culture flasks (Falcon Plastics No.
3024) for 30 min at 37°C in RPMI containing
10% heat-inactivated normal human serum
(NHS). Non-adherent leucocytes were separ-
ated further by passage through nylon wool
columns (Julius et al., 1973). Eluted cells con-
sisted of 85-92% E rosette-forming cells with
1-4% cellsforming EArosettes. Allprocedures
were performed with RPMI and 10% NHS.
Tumour cell suspensions.-Details of the
separation of cell suspensions from tumour
specimens has been described elsewhere (Vose
et al., 1977). Tumour was minced in RPMI+
10% NHS and forced through a 60-mesh
stainless steel mesh. The resulting suspension
was separated by stepwise application of
enzyme treatment (0.1% trypsin: Sigma
St Louis, Mo., U.S.A.) for 1 min at room tem-
perature in the presence ofDNAse to prevent
clumping, density and velocity sedimenta-
tions on gradients of Ficoll-Isopaque or
bovine serum, and short-term adherence in
culture flasks to deplete macrophages. Separa-
tion was continued until contamination by
red cells, macrophages and lymphocytes had
been reduced to less than 5%. Only cell
preparations with a viability of greater
than 85% were used as targets in 5lCr release
assays.
Cell line.-K562, originally derived from a
patient with chronic myeloid leukaemia in
blast crisis (Lozzio and Lozzio, 1973), was
maintained in suspension culture in RPMI
+10% foetal calf serum.
Storage and tumour cells.-Samples of
tumour cells (2 x 106-5 x 106) were stored
frozen over liquid N2 for use as targets in tests
with cultured lymphocytes. Cells were sus-
pended in 0-5 ml RPMI containing 40% NHS
and 0 5 ml 20% DMSO in RPMI added drop-
wise. Ampoules were frozen at 1°C/min to
-20°C and stored. After thawing, cells were
diluted to 10 ml, centrifuged and resuspended
in RPMI+10% NHS. Dead cells were re-
moved, when necessary, by centrifugation on
Ficoll-Isopaque gradients.
In vitro generation of cytotoxic effectors.-
Aliquots(2.5 X 106)oflymphocytes weremixed
with 5 X 105 tumour cells in RPMI+10%
NHS in glass tubes. They were incubated for
6 days at 37°C in a humidified atmosphere of
5% CO2. After washing, cells were resuspend-
ed in RPMI+10% NHS and used as effectors
in cytotoxicity assays. Controls consisted of
lymphocytes cultured alone.
Cytotoxicity assays.-Target cells (106) were
labelled in 0 5 ml RPMI by addition of 100
,tCi Sodium 51Cr Chromate specific activity
100-350 ,uCi/,g (Radiochemical Centre,
Amersham). Following incubation for 2 h
at 37°C they were washed x 4 and resuspend-
ed in RPMI+10% NHS. Cells (104) were dis-
pensed into tubes and lymphocytes added to
give an effector:target ratio of 50: 1. In tests
with cultured lymphocytes after in vitro
generation the effector:target ratio was 20: 1.
The fluid volume was adjusted to 0-6 ml with
medium. Samples (0-2 ml) of the supernate
were removed after 4 h incubation at 370C
andtheradioactivity inthe supernatesamples
and remaining pellet counted in a gamma
counter. Spontaneous 51Cr release was mea-
sured from target cells incubated in medium
and maximum 51Cr release obtained by lysis
ofthe cells with Triton X-100.
Percentage 51Cr release from each tube was
calculated as follows:
% 51Cr release=
3 X counts in supernate sample 100
total counts in supernate and pellet x
Cytotoxicity was derived from the formula:
Cytotoxicity=
%/ release test-spontaneous release X 100
Maximum release-spontaneous release
All tests in which spontaneous release ex-
ceeded 50% were discarded. Cytotoxicities of
greater than 20% were uniformly significant
by the Mann-Whitney U test.
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RESULTS
Blood lymphocytes from 47 patients
with lung neoplasia have been tested for
cytotoxicity against cells isolated from the
autologous tumour (Fig. 1). Significant re-
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limited to 2 cases (cytotoxicity 33%,
33%) with one of these samples also posi-
tive against the autologous specimen. In
10 cases tested, reactivity was detectable
against autologous but not against allo-
geneic lung tumour cells. In a further 13
cases, lymphocytes from lung cancer
patients were tested against cells derived
from tumours arising outside the lung
(breast, colon and hypernephroma). One
significant reaction was detected against a
breast carcinoma (Table II). In 9 tests in
TABLE II.-Cytotoxicity of blood lympho-
cytes against tumour target cells
Source of
effectors
Lung Ca.
Lung Ca.
Lung Ca.
Non-lung tumours
Healthy donors
Autologous Allogeneic
lung lung
FIG. 1. Cytotoxicity of blood lymphocytes
for autologous and allogeneic lung tumour
targets.
activity was found in 15 of these patients
(cytotoxicity 20-74%). In 32 ofthese cases
itwasalsopossibletotestreactivityagainst
cells isolated from allogeneic lung tumours
on the same day. An example ofthese tests
is shown in Table I. Cytotoxicity was
TABLE I.-Cross test for specificity of
lymphocytotoxicity
% Cytotoxicity with cell from
Tu2217
Lymphocyte source (Adeno-
I carci-
Patient Diagnosis Tu1284 Tu12l7 Tu1292 noma)
1284 Squamous
cell Ca 27 (36) 17 (19) NT (27) 17 (48)
1217 Squamous
cell Ca 12 36 NT 0
1292 Adenocar-
cinoma 10 6 51 0
Healthy
donor 10 0 7 NT
No. in parentheses indicate % spontaneous 51Cr
release.
Targets
Autologous tumour
Allogeneic tumour
Non-lung tumours
Lung Ca.
Lung Ca.
Cyto-
toxicity*
15/47
2/32
1/13
1/9
0/14
*No. positive/No. tested.
which lung tumour targets were exposed
to lymphocytes from patients with cancer
outside the lung, reactivity was found in
one combination (osteosarcoma against
squamous carcinoma). Lymphocytes from
healthy donors did not show reactivity
against lung tumour derived targets.
The 15 positive cases were not confined
to any particular histological type of pul-
monary malignancy (Table III), although
in 5 cases of oat-cell carcinoma examined
none showed significant reactivity.
In those cases in which pathology was
available, reactivity was found in 2/15
patients with disease in the draininglymph
nodes and 6/15 in whom no local spread
was detected. No association between the
degree ofdifferentiation ofthe tumour and
cytotoxicity was apparent.
TABLE III.-Autologous lymphocyte re-
activity in different histological types of
pulmonary neoplasia
Histology
Squamous cell Ca.
Oat cell Ca.
Adenocarcimona
Undifferentiated Ca.
Adenoid Ca.
Cytotoxicity
9/22
0/5
4/13
1/5
1/2
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Fie. 2. Cytotoxicity of lymphocytes from
lung cancer patients with and without
local metastases for K562.
Twenty-nine lymphocyte samples were
tested against the K562 cell line (Fig. 2).
Cytotoxicity varied widely (7-84%) with
22 patients showing significant reactivity.
In this series no differentiation between
patients with and without local spread was
noted.
In 1 7 patients sufficient material was
recovered to allow experiments of in vitro
generation ofcytotoxicity to be performed
(Fig. 3, Table V). Three cases (7, 9 and 12)
showed reactivity on primary testing.
After culture for 6 days, 13 samples
showed significant cytotoxicity for auto-
logous cells including 2 of those positive
on primary testing. In 4 cases (8, 9, 10, 13),
culture oflymphocytes alone was sufficient
to induce cytotoxic potential, increased
reactivity in the presence of tumour cells
being determined in 2 of these (9 and 10).
Elevated cytotoxicity was induced by cul-
ture with tumour cellsin I I casescompared
with lymphocytes cultured alone.
Preparations which showed autologous
1 2 3 4 5 6 7 8 9 10 1 1 12 13
Case number
FIG. 3. In1 vitro generation of cytotoxicity against human lung tumouLr cells. Numbers on columns
indicate the 00 cytotoxicity oflymphocytes cultured alone (side) and with tumour (top). In Case 13.
cytotoxicity was greater in lymphocytes alone than in those cultured with tumour.
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TABLE IV.-Cytotoxicity of lymphocytes
from lung cancer patients after co-cultiva-
tion with autologous tumour cells
Donor
6
7
8
9
10
11
12
13
1
Cul
w
A
Tu
Auto-
ltured logous
,ith: tumour
lone 6*
mour 20
,, 0
78
24
27
,, 23
76
,, 32
42
6
26
,, 0
0
51
16
,, 0
30
* % Cytotoxicity.
Target
cells
K562
0
0
11
0
7
15
1
3
21
25
0
0
0
0
0
3
Allogeneic
tumour
15 Sarcoma
0 Glioma
0
1 Lung
0 Lung
0
14 Glioma
reactivity after culture were tested for
cytotoxicity against the K562 cell line.
Only one (Case 10) showed significant cyto-
toxic potential (Table IV). No prepara-
tion in which cytotoxicity against auto-
logous targets was induced by co-cultiva-
tion was cytotoxic for allogeneic cells
(Table IV). Specificity tests with a further
6 cases, ofwhich 4 were oflung carcinoma,
are shown in Table V. The effectors, all of
which had been cultured with autologous
tumour cells, were tested for cytotoxicity
against different targets. Again cytotoxi-
city was restricted to the autologous com-
binations. Thus, following co-cultivation
with autologous lung tumour, cytotoxicity
was found against 13 samples of which
specificity controls using allogeneictumour
targets were carried out and were negative
in 8. A further 4 of these samples were
tested against K562, one positive reaction
being recorded.
DISCUSSION
Cytotoxicity in blood lymphocytes from
patients with pulmonary neoplasia has
been detected almost exclusively in this
study against cells isolated from auto-
logous lung tumours. Reactions against
allogeneic tumour cells from lung, colon,
breast and kidney were rare. These data
would, therefore, support the existence of
individually specific cell-surface antigens
in lung malignancies. Alternatively, they
are consistent with a restriction of cyto-
toxicity against cross-reacting antigens by
a requirement for histocompatibility be-
tween effector and target cells. At present
the two cannot be differentiated in this
system.
The restricted autologous reactivity
contrasts with previously described data
showing that immunological responses in
lung tumours were confined by tissue
boundaries. Lymphocytes reacted most
frequently with the targets cultured from
lung tumours in cytotoxicity tests (Hell-
strom et al., 1971; Baldwin et al., 1973;
Voseetal., 1975; Pierce and DeVald, 1975)
TABLE V.-Specificity ofin-vitro-generated killer cells against autologous and
allogeneic tumour targets
Lymphocyte donor
r
A
No. Diagnosis
1115 Undifferentiated mesenchymal
tumour
2222 Squamous cell Ca. (lung)
2223 Adenocarcinoma lung
782 Glioma
2240 Squamous cell Ca. (lung)
2225 Squamous cell Ca.
% Cytotoxicity with cells from:
Tu15 Tu2222 Tu2223 Tu782
47 (23) NT (35) 13 (36)
0 26 2
NT 0 24
0 0 0
Tu2240 Tu2225 Tu2223
(adeno-
carcinoma)
72 (26) 10 (34) 0 (12)
7 24 0
NT (41)
NT
NT
28
Numbers in parentheses indicate % spontaneous 51Cr release.
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or with lung homogenates in leukocyte
migration inhibition assays (Boddie et al.,
1975; Vose et al., 1977a). Reactions in skin
testing with tumour homogenates also
showed organ-related reactivity (Hollins-
head et al., 1974). The implication ofthese
studies is that tumours from the lung share
common antigenic specificities not present
on neoplasms arising at other sites. Re-
activity against apparently non-malignant
lung tissue in migration inhibition assays
(Vose et at., 1975, 1977a; Boddie et al.,
1975), the involvement of NK reactions
and effector functions of non-T lympho-
cytes (Vose and Moore, 1977) against cul-
tured allogeneic targets in cytotoxicity
tests, may to some extent obscure this in-
terpretation. However, the apparent auto-
logous reactivity could arise from histo-
compatibility restriction ofcytotoxicity to
a common lung-tumour-associated anti-
gen. It can also be envisaged that both
individually specific and cross-reacting
antigenic markers are expressed in pul-
monary neoplasia and are selectively re-
vealed by reactions in the different assays
of cellular immunity.
Cytotoxicity in the present studydidnot
relate to the histological type of lung
tumour or to the presence oftumour in the
tumour-draining lymph node. Assays of
NK activity against the K562 cell line also
failed to reveal an association with the
stage of disease, although a fall in NK
potential has been described in other
tumour systems (Pross and Baines, 1976;
Takasugi et al., 1977). Lung carcinoma is
often advanced by the time it presents, so
failure to relate cytotoxic effects to stage
ofdisease may be an indication ofageneral
depression of immune function in this
group (Eilber and Morton, 1970; Dalbow et
al., 1977). Such a functional depression is
suggested by experiments showing that
co-cultivation of blood lymphocytes with
autologous tumour can lead to the genera-
tion of cytotoxic effectors which again
show specificity for the autologous tumour.
This generation is uniformly accompanied
by blastogenesis responses in the mixed
lymphocyte target cell interaction assay
(Vose et al., 1978) and suggests a block of
the development of killer cells from cir-
culating pre-killer cells in the lung cancer
patient.
The expansion of the cytotoxic poten-
tial of blood lymphocytes with the reten-
tion of selectivity provides a means by
which the spectrum of antigenic activity
in human pulmonary neoplasia can be
more fully investigated. Such studies pro-
vide a necessary prerequisite to an under-
standing of neoantigen expression follow-
ing malignant transformation in man. The
difficulty ofobtaining targets from normal
lung areas must also be overcome before
definitive statements of human tumour
antigenicity can be made.
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